search

1-20 of 31

Save search

Sort by

Sort Order Select

Journal Article

MDB-65. RESULTS FROM THE SJ-ELIOT PHASE 1 CLINICAL TRIAL EVALUATING PREXASERTIB (LY2606368) IN COMBINATION WITH CYCLOPHOSPHAMIDE OR GEMCITABINE FOR CHILDREN AND ADOLESCENTS WITH REFRACTORY OR RECURRENT MEDULLOBLASTOMA

PDF

Nicholas G Gottardo and others

Neuro-Oncology, Volume 26, Issue Supplement_4, June 2024, Page 0, https://doi.org/10.1093/neuonc/noae064.514

Published: 18 June 2024

Journal Article

DIPG-84. PHASE 1 DOSE-ESCALATION STUDY OF ACT001 IN PEDIATRIC PATIENTS WITH ADVANCED BRAIN AND SOLID TUMORS SHOWS ACTIVITY IN DIFFUSE MIDLINE GLIOMA (DMG)

PDF

David S Ziegler and others

Neuro-Oncology, Volume 26, Issue Supplement_4, June 2024, Page 0, https://doi.org/10.1093/neuonc/noae064.137

Published: 18 June 2024

Journal Article

DIPG-67. RE-IRRADIATION PRACTICES AND OUTCOMES IN PATIENTS WITH DIPG/DMG: A REPORT FROM THE INTERNATIONAL DIPG REGISTRY

PDF

Natasha Pillay-Smiley and others

Neuro-Oncology, Volume 26, Issue Supplement_4, June 2024, Page 0, https://doi.org/10.1093/neuonc/noae064.120

Published: 18 June 2024

Journal Article

Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: Safety, efficacy, biomarker, and pharmacokinetics—CheckMate 908

PDF

Ira J Dunkel and others

Neuro-Oncology, Volume 25, Issue 8, August 2023, Pages 1530–1545, https://doi.org/10.1093/neuonc/noad031

Published: 20 February 2023

Supplementary data

Journal Article

Efficient detection and monitoring of pediatric brain malignancies with liquid biopsy based on patient-specific somatic mutation screening

PDF

Marija Kojic and others

Neuro-Oncology, Volume 25, Issue 8, August 2023, Pages 1507–1517, https://doi.org/10.1093/neuonc/noad032

Published: 09 February 2023

Supplementary data

Journal Article

MEDB-74. Serial assessment of measurable residual disease in medulloblastoma liquid biopsies

PDF

Paul Northcott and others

Neuro-Oncology, Volume 24, Issue Supplement_1, June 2022, Pages i123–i124, https://doi.org/10.1093/neuonc/noac079.448

Published: 03 June 2022

Journal Article

IMMU-08. Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: efficacy, safety, biomarker, and pharmacokinetic results from Checkmate 908

PDF

Ira J Dunkel and others

Neuro-Oncology, Volume 24, Issue Supplement_1, June 2022, Pages i82–i83, https://doi.org/10.1093/neuonc/noac079.301

Published: 03 June 2022

Journal Article

DIPG-25. Patterns of cerebrospinal fluid diversion and survival in children with diffuse intrinsic pontine glioma: a report from the International Diffuse Intrinsic Pontine Glioma Registry

PDF

Tabitha Cooney and others

Neuro-Oncology, Volume 24, Issue Supplement_1, June 2022, Pages i23–i24, https://doi.org/10.1093/neuonc/noac079.082

Published: 03 June 2022

Journal Article

Characteristics of children ≤36 months of age with DIPG: A report from the international DIPG registry

PDF

Allison L Bartlett and others

Neuro-Oncology, Volume 24, Issue 12, December 2022, Pages 2190–2199, https://doi.org/10.1093/neuonc/noac123

Published: 12 May 2022

Supplementary data

Journal Article

Accuracy of central neuro-imaging review of DIPG compared with histopathology in the International DIPG Registry

PDF

Margot A Lazow and others

Neuro-Oncology, Volume 24, Issue 5, May 2022, Pages 821–833, https://doi.org/10.1093/neuonc/noab245

Published: 20 October 2021

Supplementary data

Journal Article

EDITOR'S CHOICE

Characteristics of patients ≥10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry

PDF

Craig Erker and others

Neuro-Oncology, Volume 24, Issue 1, January 2022, Pages 141–152, https://doi.org/10.1093/neuonc/noab140

Published: 11 June 2021

Journal Article

HGG-14. ACT001 – A PROMISING THERAPEUTIC FOR DIFFUSE INTRINSIC PONTINE GLIOMAS

PDF

Dannielle Upton and others

Neuro-Oncology, Volume 23, Issue Supplement_1, June 2021, Page i20, https://doi.org/10.1093/neuonc/noab090.080

Published: 01 June 2021

Journal Article

MBRS-20. CSF-DERIVED CIRCULATING TUMOR DNA AS A BIOMARKER FOR DISEASE PROGRESSION AND TUMOR EVOLUTION IN MEDULLOBLASTOMA

PDF

Anthony Pak-Yin Liu and others

Neuro-Oncology, Volume 22, Issue Supplement_3, December 2020, Pages iii401–iii402, https://doi.org/10.1093/neuonc/noaa222.536